Cited by 748Extracellular vesicles in diseaseRNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment

Open access
Kojima, Ryosuke, Bojar, Daniel, Rizzi, Giorgio, Hamri, Ghislaine Charpin-El, El-Baba, Marie Daoud, Saxena, Pratik, Ausländer, Simon, Tan, Kelly R. +1 more·2018·Nature Communications

Abstract

Exosomes are cell-derived nanovesicles (50–150 nm), which mediate intercellular communication, and are candidate therapeutic agents. However, inefficiency of exosomal message transfer, such as mRNA, and lack of methods to create designer exosomes have hampered their development into therapeutic interventions. Here, we report a set of EXOsomal transfer into cells (EXOtic) devices that enable efficient, customizable production of designer exosomes in engineered mammalian cells. These genetically encoded devices in exosome producer cells enhance exosome production, specific mRNA packaging, and delivery of the mRNA into the cytosol of target cells, enabling efficient cell-to-cell communication without the need to concentrate exosomes. Further, engineered producer cells implanted in living mice could consistently deliver cargo mRNA to the brain. Therapeutic catalase mRNA delivery by designer exosomes attenuated neurotoxicity and neuroinflammation in in vitro and in vivo models of Parkinson’s disease, indicating the potential usefulness of the EXOtic devices for RNA delivery-based therapeutic applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-03733-8

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Engineered exosomes carrying RVG-Lamp2b can efficiently cross the blood-brain barrier and deliver catalase mRNA, resulting in a reduction of 6-OHDA-mediated neuroinflammation in a mouse model of Parkinson's disease.

    “The designed exosome carrying RVG-Lamp2b was able to efficiently cross the blood–brain barrier (BBB) and deliver the catalase mRNA, resulting in a reduction of 6-OHDA-mediated neuroinflammation in a mouse model of Parkinson’s disease [101, 103].”
  • EXOtic system carrying RVG-Lamp2b successfully crossed the BBB and delivered catalase mRNA.

    “The developed system carrying RVG-Lamp2b successfully crossed the BBB and delivered catalase mRNA.”
  • This reduced neuroinflammation induced by 6-OHDA and neurotoxicity in a Parkinson's mouse model.

    “This reduced neuroinflammation induced by 6-OHDA and neurotoxicity in a Parkinson's mouse model [101].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kojima, R., Bojar, D., Rizzi, G., Hamri, G. C.-E., El-Baba, M. D., Saxena, P., Ausländer, S., Tan, K. R., & Fussenegger, M.
Affiliations
  • ETH Zurich (CH)
  • University of Basel (CH)
  • Instituts Universitaires de Technologie (FR)
Corresponding author
Fussenegger, Martin
Venue
Nature Communications
Published
2018-04-03
Volume
9
Issue
1
Pages
1305-1305
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2795868806
Cited by
748
References
58
Citations by year
2026: 77 · 2025: 101 · 2024: 130 · 2023: 128 · 2022: 113 · 2021: 84 · 2020: 60 · 2019: 44 · 2018: 9 · 2016: 1
FWCI
17.52
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • edoc (University of Basel) (submittedVersion)
  • ETH Zürich Research Collection (cc-by)
Funders
  • Karolinska Institutet
  • FP7 Ideas: European Research Council (321381)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
exosome engineering, mRNA delivery, Parkinson's disease, catalase, cell-to-cell communication, neuroinflammation, neurotoxicity, RNA therapeutics
MeSH terms
Animals, Brain, Catalase, Cell Communication, Cytosol, Female, HeLa Cells, Humans, Mice, Inbred C57BL, Parkinson Disease, RNA, Messenger, Genetic Therapy, Drug Delivery Systems, Electroporation, 3' Untranslated Regions, MicroRNAs, Cell Line, Tumor, Mice, Nanoparticles, Cerebrum, Exosomes, HEK293 Cells, Synthetic Biology, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review